Investor Relations :: Benitec Biopharma Inc. (BNTC)

Latest News

Sep 21, 2023

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

View Press Release

Aug 11, 2023

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Aug 8, 2023

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

View All News

Corporate Presentation, July 2023

View Presentation

FY 2023

Fiscal Year Ended Jun 30, 2023

Earnings Release

10-K

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2023

Company Overview

Benitec Biopharma Inc. is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.

View Management Team View Board of Directors

Investor Contact Information

Company

Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545

Investor Relations

William Windham
VP, Solebury Trout
T: 646-378-2946
wwindham@soleburytrout.com

Transfer Agent

Computershare Investor Services
P.O. Box 505005
Louisville, KY 40233-5005
T: 781-575-3100